Tawseef Dar

Tawseef Dar

Auto-generated profile, based on publicly available information

Tawseef Dar

Division of Cardiovascular Diseases, Cardiovascular Research Institute, University of Kansas Hospital & Medical Center, Kansas City, Kansas

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2019 in Current Treatment Options in Cardiovascular Medicine
Verified
Journal Article
Closed access
PDF file
TDTawseef Dar
Tawseef Dar
ARAzar Radfar
Azar Radfar
SAShady Abohashem
Shady Abohashem
RPRoger K. Pitman
Roger K. Pitman
ATAhmed Tawakol
Ahmed Tawakol
MOMichael Osborne
Michael Osborne

1 February 2019 in Heart Rhythm
Verified
Journal Article
Closed access
BYBharath Yarlagadda
Bharath Yarlagadda
TDThomas Deneke
Thomas Deneke
MTMohit Turagam
Mohit Turagam
TDTawseef Dar
Tawseef Dar
SPSwathi Paleti
Swathi Paleti
DLDhanunjaya Lakkireddy
Dhanunjaya Lakkireddy

14 February 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SAShady Abohashem
Shady Abohashem
MOMichael Osborne
Michael Osborne
TDTawseef Dar
Tawseef Dar
NNNicki Naddaf
Nicki Naddaf
TATaimur Abbasi
Taimur Abbasi
ATAhmed Tawakol
Ahmed Tawakol
Air pollution [i.e. particulate matter with diameter <2.5 μm (PM2.5)] is a risk factor for major adverse cardiovascular events (MACE). While PM2.5 promotes leucopoiesis and atherosclerotic inflammation in experimental models, it is unknown whether this occurs in humans. We tested in humans (a) whether PM2.5 associates with higher leucopoietic tissue activity and arterial inflammation (ArtI), (ii) whether these associations persist after accounting for the effects of potential confounders including socioeconomics, traffic noise, and risk factors, and (iii) whether these tissue effects mediate the association between air pollution and MACE. Individuals (N = 503) without cardiovascular disease (CVD) or active malignancy underwent 18 F-fluorodeoxyglucose positron emission tomography/computed tomography. Major adverse cardiovascular event was adjudicated over 5 years of follow-up. Leucopoietic tissue activity (in bone marrow and spleen) as well as ArtI were measured. Annual PM2.5 levels were assessed at each individual’s home address. At baseline, higher PM2.5 associated with increased leucopoietic activity [standardized (95% CI): 0.129 (0.042, 0.215), P = 0.004] as well as ArtI [0.088 (0.006, 0.171), P = 0.036] after adjusting for CVD risk factors. Over a median 4.1 years, 40 individuals experienced MACE. PM2.5 exposure associated with MACE [Cox HR (95% CI): 1.404 (1.135, 1.737), P = 0.002], remaining significant after adjustment for CVD risk factors and other potential confounders. Mediation analysis demonstrated that increased leucopoietic activity and ArtI serially mediate the link between PM2.5 exposure and MACE. Higher air pollution exposure associates with heightened leucopoietic activity and ArtI and independently predicts MACE through a biological pathway that includes higher leucopoietic activity and ArtI in series. The hypothesized mechanism linking air pollution exposure to major adverse cardiovascular disease events through an up-regulated leucopoietic-arterial axis (solid red arrows).

1 September 2018 in Heart Rhythm
Verified
Journal Article
Closed access
VPValay Parikh
Valay Parikh
VSVijay Swarup
Vijay Swarup
JHJacob Hantla
Jacob Hantla
VVVenkat Vuddanda
Venkat Vuddanda
TDTawseef Dar
Tawseef Dar
DLDhanunjaya Lakkireddy
Dhanunjaya Lakkireddy

14 April 2019 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
PDF file
KCKhalid Hamid Changal
Khalid Hamid Changal
MSMubbasher Ameer Syed
Mubbasher Ameer Syed
TDTawseef Dar
Tawseef Dar
MMMuhammad Asif Mangi
Muhammad Asif Mangi
MSMujeeb Abdul Sheikh
Mujeeb Abdul Sheikh
Introduction. Common femoral endarterectomy (CFE) has been the therapy of choice for common femoral artery atherosclerotic disease (CFA-ASD). In the past, there was inhibition to treat CFA-ASD endovascularly with stents due to fear of stent fracture and compromise of future vascular access site. However, recent advances and new evidence suggest that CFA may no longer be a ‘stent-forbidden zone’. In the light of new evidence, we conducted a meta-analysis to determine the use of endovascular treatment for CFA-ASD and compare it with common femoral endarterectomy in the present era.Methods. Using certain MeSH terms we searched multiple databases for studies done on endovascular and surgical treatment of CFA-ASD in the last two decades. Inclusion criteria were randomized control trials, observational, prospective, or retrospective studies evaluating an endovascular treatment or CFE for CFA-ASD. For comparison, studies were grouped based on the treatment strategy used for CFA-ASD: endovascular treatment with selective stenting (EVT-SS), endovascular treatment with routine stenting (EVT-RS), or common femoral endarterectomy (CFE). Primary patency (PP), target lesion revascularization (TLR), and complications were the outcomes studied. We did proportional meta-analysis using a random-effect model due to heterogeneity among the included studies. If confidence intervals of two results do not overlap, then statistical significance is determined.Results. Twenty-eight studies met inclusion criteria (7 for EVT-RS, 8 for EVT-SS, and 13 for CFE). Total limbs involved were 2914 (306 in EVT-RS, 678 in EVT-SS, and 1930 in CFE). The pooled PP at 1 year was 84% (95% CI 75-92%) for EVT-RS, 78% (95% CI 69-85%) for EVT-SS, and 93% (95% CI 90-96%) for CFE. PP at maximum follow-up in EVT-RS was 83.7% (95% CI 74-91%) and in CFE group was 88.3% (95% CI 81-94%). The pooled target lesion revascularization (TLR) rate at one year was 8% (95% CI 4-13%) for EVT-RS, 19% (95% CI 14-23%) for EVT-SS, and 4.5% (95% CI 1-9%) for CFE. The pooled rate of local complications for EVT-RS was 5% (95% CI 2-10%), for EVT-SS was 7% (95% CI 3 to 12%), and CFE was 22% (95% CI 14-32%). Mortality at maximum follow-up in CFE group was 23.1% (95% CI 14-33%) and EVT-RS was 5.3% (95% CI 1-11%).Conclusion. EVT-RS has comparable one-year PP and TLR as CFE. CFE showed an advantage over EVT-SS for one-year PP. The complication rate is lower in EVT RS and EVT SS compared to CFE. At maximum follow-up, CFE and EVT-RS have similar PP but CFE has a higher mortality. These findings support EVT-RS as a management alternative for CFA-ASD.

1 July 2018 in Heart Rhythm
Verified
Journal Article
Closed access
TDTawseef Dar
Tawseef Dar
MAMuhammad R. Afzal
Muhammad R. Afzal
BYBharath Yarlagadda
Bharath Yarlagadda
SKShelby Kutty
Shelby Kutty
QSQuanliang Shang
Quanliang Shang
DLDhanunjaya Lakkireddy
Dhanunjaya Lakkireddy